Tagged with Regulator

Pharma The CEO of IPASA reveals how over the last ten months the priority has been to reach out to different stakeholders, rebuilding trust with the department of health, with patients and physicians; why a National Health Insurance scheme should be established to act as a true merger between the public and private…

Pharma The Head of the Department of Medical Oncology at the Pitié-Salpêtrière Hospital reveals how France is the only country in the world with universal and unlimited access to healthcare, how the oncology world in France is committed to changing the perception of cancer and why the only way to prevent…

Pharma Wanda Velez, president of the Puerto Rico Medical Association, discusses the history of the organization, which dates back to 1902. She also describes the Association’s voluntary role in contrast to the Colegio de Medicos, which by law is compulsory for all Puerto Rican physicians to join. Can you describe your…

Pharma José Luis Rodríguez, CEO of Hospital Pavia Santurce, explains how budget cuts to Puerto Rico’s healthcare system will have a dramatic impact on the country’s hospitals, and outlines how medical tourism can be promoted more to bring more patients to the island. What is your current assessment of Puerto Rico’s…

Pharma The Puerto Rico Trade and Export Company (CCE) helps small and medium-sized enterprises (SMEs) stimulate their business in Puerto Rico and abroad. Frankie Chévere, CCE’s executive director, discusses the successes of the agency since 2013. You came to CCE in 2013; what were the first challenges you had to address…

Pharma The chairman of PHARMISA reveals how pharmaceuticals has been designated as one of eight priority sectors of South African Government’s Industrial Policy Action Plan (IPAP), how South African life expectancy has increased by around eight years over the last decade, placing further strain on the public healthcare system, and why…

Pharma The President of Cristers discusses the history of generic drugs in France and what steps can be taken to increase generics penetration, while also outlining the ‘cooperative’ business model behind Cristers’ meteoric rise – with a sixty-fold increase in turnover in less than a decade – from its creation in…

universal healthcare Berlin Pharmaceutical Industry’s CEO, Amal Naj, explains how he has grown the company, its next regional and medical targets, and his vision for its future. What has led to Berlin Pharmaceutical’s success over the last five years?    In 2010, the market was going through a major transition due to the progressive…

regulator The technical & RA director and the managing director of Qually Corporacion explain how authorized third partied act as an extension of the regulative body, Cofepris, helping to assure that generics obtain a certain standard before they are released on the market, that is why the main challenge is to…

regulator The president of the Turkish Drug and Medical Device Agency (TITCK) discusses new initiatives and reforms being carried out by his agency, including its work towards becoming a PIC/s member, and the introduction of several changes designed to accelerate timelines for GMP certifications and marketing authorizations.   You began your TITCK…

Romania The director of Romania’s national pharmaceuticals regulator outlines how his institution is embracing health technology assessment (HTA) capabilities and the transformative changes this will have on the local industry. He also speaks frankly about hot topics sweeping the sector: among them the pressing need for increased regulation of medical devices…

AstraZeneca Rodrigo Fernandez became country president of AstraZeneca Central America, Caribbean, and Middle Andean Countries (CAMCARMAC) in July 2013. He discusses the challenges across the region for regulation and distribution channels, with an emphasis on the complexities of the Peruvian market. What were your initial priorities when you became head of…